TABLE 4.
Treatment-Related AEs Reported by ≥5% of Healthy Adult Participants
| Viloxazine Extended-Release Alone (n = 35), n (%) | Lisdexamfetamine Alone (n = 35), n (%) | Combination (n = 35), n (%) | Overall (n = 36), n (%) | |
|---|---|---|---|---|
| Any AE | 7 (20.0) | 8 (22.9) | 11 (31.4) | 13 (36.1) |
| Nausea | 3 (8.6) | 0 | 5 (14.3) | 7 (19.4) |
| Dry mouth | 1 (2.9) | 1 (2.9) | 3 (8.6) | 4 (11.1) |
| Dizziness | 2 (5.7) | 1 (2.9) | 1 (2.9) | 4 (11.1) |
| Somnolence | 3 (8.6) | 0 | 0 | 3 (8.3) |
| Headache | 0 | 2 (5.7) | 2 (5.7) | 3 (8.3) |
| Feeling hot | 1 (2.9) | 1 (2.9) | 1 (2.9) | 3 (8.3) |
| Increased Energy | 0 | 3 (8.6) | 1 (2.9) | 3 (8.3) |
| Decreased appetite | 0 | 2 (5.7) | 1 (2.9) | 3 (8.3) |
| Head discomfort | 1 (2.9) | 1 (2.9) | 0 | 2 (5.6) |
| Vomiting | 1 (2.9) | 0 | 1 (2.9) | 2 (5.6) |
| Palpitations | 0 | 0 | 2 (5.7) | 2 (5.6) |
| Hot flush | 2 (5.7) | 1 (2.9) | 0 | 2 (5.6) |